The purpose of ORACLE is to demonstrate the ability of a novel ctDNA assay developed by Guardant Health to detect recurrence in individuals treated for early-s…

Bladder CarcinomaUreter CarcinomaRenal Pelvis Carcinoma+14 more

~Estimated

~$10 – $1,050

Guardant Health, Inc.NCT05059444

Phase 1

A Phase 1/2 Open Label, Dose Escalation and Expansion Study of MDNA11, IL-2 Superkine, Administered Alone or in Combination With Immune Checkpoint Inhibitor in Patients With Advanced Solid Tumors

This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal o…

Advanced Solid TumorUnresectable Solid TumorClear Cell Renal Cell Carcinoma+34 more

~Estimated

Observational

Randomized, Controlled Trial of an Electronic Decision Aid for Genetic Testing in Inherited Cancer Syndromes

This is a randomized trial to evaluate the effectiveness of an electronic decision aid tool versus a traditional genetic counselor session for multi-gene panel…

Epithelial Ovarian CarcinomaPancreas Adenocarcinoma

~Estimated

~$10 – $6,250

Massachusetts General HospitalNCT05470920

~$10 – $8,750

Medicenna Therapeutics, Inc.NCT05086692